BACKGROUND The appropriate thresholds for decisions on the cost-effectiveness of medical interventions remain controversial, especially in 'end-of-life' situations. Evidence of the values placed on different types of health gain by the general public is limited. METHODS Across nine European countries, 17,657 people were presented with different hypothetical health scenarios each involving a g...

OBJECTIVES To investigate the long-term clinical and economic outcomes associated with exenatide versus insulin glargine as "add-on" treatments to oral therapy in individuals with Type 2 diabetes inadequately controlled with combination oral agents in the Swiss setting. METHODS A computer simulation model of diabetes was used to project complications, life expectancy, quality-adjusted life ex...

OBJECTIVES The analysis goal was to estimate incremental cost-effectiveness ratios (ICERs) for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial patients who received cardiac resynchronization therapy (CRT) via pacemaker (CRT-P) or pacemaker-defibrillator (CRT-D) in combination with optimal pharmacological therapy (OPT) relative to patients with OP...

BACKGROUND & AIMS The increasing incidence of hepatocellular carcinoma (HCC) in the United States has significant health and economic consequences. Ultrasound (US) surveillance is recommended for patients with cirrhosis because of their high risk of HCC and improving treatment outcomes for small tumors. We assessed the costs, clinical benefits, and cost effectiveness of US surveillance and alte...

Introduction: Alteplase is widely used as an intravenous thrombolytic drug in acute ischemic stroke (AIS). Recently however, tenecteplase, a modified form of tissue plasminogen activator, has been shown to increase early recanalization rate and proven be non-inferior with similar safety profile compared alteplase. This study aims evaluate the cost-effectiveness 0.25 mg/kg tenecteplase versus 0....

Background: Cardiovascular (CV) diseases remain a leading and costly cause of death globally. Patients with previous CV events are at high risk recurrence. Secondary prevention therapies improve factor control reduce disease costs. Objectives: To assess the cost-effectiveness polypill strategy (CNIC-Polypill) compared loose combination monocomponents to factors in patients coronary heart or str...

CMS operates the quality improvement organization (QIO) program to improve the quality of care delivered to Medicare beneficiaries. Although there have been several studies regarding the effectiveness of this program, there have not been studies regarding this program's value. This article seeks to answer the value question using costutility analysis. Although additional research is warranted, ...

BACKGROUND Studies on the immunotherapy for Alzheimer's disease (AD) have increasingly gained attention since 1990s. However, there are pros (preventing of AD) and cons (incurred cost and side effects) regarding the administration of immunotherapy. Up to date, there has been lacking of economic evaluation for immunotherapy of AD. We aimed to assess the cost-effectiveness analysis of the vaccina...

ObjectivesUncontrolled hypertension is a common cause of cardiovascular disease, which the deadliest and costliest chronic disease in United States. Pharmacists are an accessible community healthcare resource equipped with clinical skills to improve management through medication therapy (MTM). Nevertheless, current reimbursement models do not incentivize pharmacists provide services. We aim inv...

BACKGROUND Clinical studies have demonstrated statistically significant reduction of breast cancer relapse and improved overall survival by adding trastuzumab for 1 year after adjuvant chemotherapy in human epidermal growth factor receptor-2 protein (HER2)/neu-positive breast cancer. The aim of this study was to analyze the cost-effectiveness of HER2/neu testing and the addition of 1-year adjuv...